Work

266P Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): Post-hoc analysis of the GeparOla trial

Year: 2024

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.209

Authors: G. Villacampa, N. Filmann, P.A. Fasching, J. Balmaña, T. Karn, F. Marmé, P. Klare, V. Mueller, C. Schem, T.N. Fehm, E. Stickeler, M. Van Mackelenbergh, B. Felder, V. Nekljudova, A. Llop-Guevara, C. Denkert, S. Loibl, V. Serra

Institutions: Vall d'Hebron Institute of Oncology, German Breast Group, Universitätsklinikum Erlangen, Vall d'Hebron Hospital Universitari, Goethe University Frankfurt, Heidelberg University, Medizinische Fakultät Mannheim, University Medical Center Hamburg-Eppendorf, Krankenhaus Jerusalem, Düsseldorf University Hospital, Universitätsklinikum Aachen, University Hospital Schleswig-Holstein, Universitätsklinikum Gießen und Marburg

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: AstraZeneca

Award: G1285239955

OpenAlex ID: W4402561458

FWCI: 0.171

Cites:

Cited by: 1

Related to: 10